Virus engineered to fight cancer shows promise in early trial

NCT ID NCT04695327

Completed Disease control Sponsor: TILT Biotherapeutics Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety and find the right dose, not to measure how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TILT-123 (a modified virus that infects and kills cancer cells while releasing immune-boosting proteins)
What this could lead to: If successful, this could point toward a new way to treat advanced solid tumors by using a virus to attack cancer and stimulate the immune system.
What could go wrong: This is an early, small Phase 1 trial focused on safety, not effectiveness. The virus may not work in all patients or could cause side effects like flu-like symptoms or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoviridae infectious disease neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Docrates Cancer Center

Helsinki, Uusima, 00180, Finland
Helsinki University Hospital

Helsinki, Uusima, 00029, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.